Surgery Today

, Volume 42, Issue 10, pp 934–939 | Cite as

Prediction of true-negative lymph node metastasis in clinical IA non-small cell lung cancer by measuring standardized uptake values on positron emission tomography

  • Tomoyoshi Takenaka
  • Tokujiro Yano
  • Yosuke Morodomi
  • Kensaku Ito
  • Naoko Miura
  • Daigo Kawano
  • Fumihiro Shoji
  • Shingo Baba
  • Koichiro Abe
  • Hiroshi Honda
  • Yoshihiko Maehara
Original Article

Abstract

Purpose

We developed a method for predicting true-negative lymph node metastases in clinical IA non-small lung cancer (NSCLC) by the combined evaluation of computed tomography (CT), 2-[18F]-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) findings and the maximum standardized uptake value (SUVmax) of primary tumors.

Methods

The subjects of this study were 94 patients with clinical stage IA NSCLC who underwent both preoperative CT and FDG-PET. We analyzed the relationship between the SUVmax of primary tumors and various clinicopathological factors to find the best method available for assessing true-negative lymph node metastasis.

Results

The pathological stages were IA (n = 80), IB (n = 4), IIA (n = 5), IIIA (n = 4), and IV (n = 1). Pathologic lymph node metastasis was recognized in nine patients and the SUVmax of these tumors ranged from 3.3 to 20.3. A SUVmax of 3.0 was defined as the cut-off point and patients were dichotomized according to this point. Tumors with SUVmax of 3.0 or less were associated with a significantly lower incidence of pleural and vascular invasion and were characterized by the degree of differentiation.

Conclusion

The SUVmax of primary tumors reflects the grade of malignancy; therefore, the combined evaluation of FDG-PET/CT findings with the SUVmax of primary tumors may help predict lymph node metastasis negativity.

Keywords

FDG-PET Non-small cell lung cancer Clinical IA 

Abbreviations

NSCLC

Non-small cell lung cancer

FDG-PET

2-[18F]-Fluoro-2-deoxy-d-glucose positron emission tomography

References

  1. 1.
    Ramsey HE, Cahan WG, Beattie EJ, Humphrey C. The importance of radical lobectomy in lung cancer. J Thorac Cardiovasc Surg. 1969;58:225–30.PubMedGoogle Scholar
  2. 2.
    Landreneau RJ, Sugarbaker DJ, Mack MJ, Hazelrigg SR, Luketich JD, Fetterman L, et al. Wedge resection versus lobectomy for stage I (T1 N0 M0) non-small-cell lung cancer. J Thorac Cardiovasc Surg. 1997;113:691–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Asamura H, Nakayama H, Kondo H, Tsuchiya R, Shimosato Y, Naruke T. Lymph node involvement, recurrence, and prognosis in resected small, peripheral, non-small-cell lung carcinomas: are these carcinomas candidates for video-assisted lobectomy? J Thorac Cardiovasc Surg. 1996;111:1125–34.CrossRefPubMedGoogle Scholar
  4. 4.
    Suzuki K, Nagai K, Yoshida J, Nishimura M, Nishiwaki Y. Predictors of lymph node and intrapulmonary metastasis in clinical stage IA non-small cell lung carcinoma. Ann Thorac Surg. 2001;72:352–6.CrossRefPubMedGoogle Scholar
  5. 5.
    Ung YC, Maziak DE, Vanderveen JA, Smith CA, Gulenchyn K, Lacchetti C, Lung Cancer Disease Site Group of Cancer Care Ontario’s Program in, et al. 18Fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer: a systematic review. J Natl Cancer Inst. 2007;99:1741–3.CrossRefGoogle Scholar
  6. 6.
    Bryant AS, Cerfolio RJ. The maximum standardized uptake values on integrated FDG-PET/CT is useful in differentiating benign from malignant pulmonary nodules. Ann Thorac Surg. 2006;82:1016–20.CrossRefPubMedGoogle Scholar
  7. 7.
    Som P, Atkins HL, Bandoypadhyay D, Fowler JS, MacGregor RR, Matsui K, et al. A fluorinated glucose analog, 2-fluoro-2-deoxy-d-glucose (F-18): nontoxic tracer for rapid tumor detection. J Nucl Med. 1980;21:670–5.PubMedGoogle Scholar
  8. 8.
    Lardinois D, Weder W, Hany TF, Kamel EM, Korom S, Seifert B, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med. 2003;348:2500–7.CrossRefPubMedGoogle Scholar
  9. 9.
    Reed CE, Harpole DH, Posther KE, Woolson SL, Downey RJ, Meyers BF, American College of Surgeons Oncology Group Z0050 trial, et al. Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer. J Thorac Cardiovasc Surg. 2003;126:1943–51.CrossRefPubMedGoogle Scholar
  10. 10.
    World Health Organization. Histological typing of lung and pleural tumors. 3rd ed. Springer: Geneva; 1999.Google Scholar
  11. 11.
    Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol. 2007;2:706–14.CrossRefPubMedGoogle Scholar
  12. 12.
    Read RC, Yoder G, Schaeffer RC. Survival after conservative resection for T1 N0 M0 non-small cell lung cancer. Ann Thorac Surg. 1990;49:391–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Yoshikawa K, Tsubota N, Kodama K, Ayabe H, Taki T, Mori T. Prospective study of extended segmentectomy for small lung tumors: the final report. Ann Thorac Surg. 2002;73:1055–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Koike T, Yamato Y, Yoshiya K, Shimoyama T, Suzuki R. Intentional limited pulmonary resection for peripheral T1 N0 M0 small-sized lung cancer. J Thorac Cardiovasc Surg. 2003;125:924–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Lee PC, Port JL, Korst RJ, Liss Y, Meherally DN, Altorki NK. Risk factors for occult mediastinal metastases in clinical stage I non-small cell lung cancer. Ann Thorac Surg. 2007;84:177–81.CrossRefPubMedGoogle Scholar
  16. 16.
    Stiles BM, Servais EL, Lee PC, Port JL, Paul S, Altorki NK. Point: clinical stage IA non-small cell lung cancer determined by computed tomography and positron emission tomography is frequently not pathologic IA non-small cell lung cancer: the problem of understaging. J Thorac Cardiovasc Surg. 2009;137:13–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Noguchi M, Morikawa A, Kawasaki M, Matsuno Y, Yamada T, Hirohashi S, et al. Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer. 1995;75:2844–52.CrossRefPubMedGoogle Scholar
  18. 18.
    Sagawa M, Higashi K, Sugita M, Ueda Y, Maeda S, Toga H, et al. Fluorodeoxyglucose uptake correlates with the growth pattern of small peripheral pulmonary adenocarcinoma. Surg Today. 2006;36:230–4.CrossRefPubMedGoogle Scholar
  19. 19.
    Suzuki K, Kusumoto M, Watanabe S, Tsuchiya R, Asamura H. Radiologic classification of small adenocarcinoma of the lung: radiologic–pathologic correlation and its prognostic impact. Ann Thorac Surg. 2006;81:419–20.CrossRefGoogle Scholar
  20. 20.
    Yoshino I, Ichinose Y, Nagashima A, Takeo S, Motohiro A, Yano T, Kyushu Lung Cancer Surgery Cooperative Group, et al. Clinical characterization of node-negative lung adenocarcinoma: results of a prospective investigation. J Thorac Oncol. 2006;1:825–31.CrossRefPubMedGoogle Scholar
  21. 21.
    De Leyn P, Lardinois D, Van Schil P, Rami-Porta R, Passlick B, Zielinski M, ESTS, et al. European trends in preoperative and intraoperative nodal staging: ESTS guidelines. J Thorac Oncol. 2007;2:357–61.CrossRefPubMedGoogle Scholar
  22. 22.
    Meyers BF, Haddad F, Siegel BA, Zoole JB, Battafarano RJ, Veeramachaneni N, et al. Cost-effectiveness of routine mediastinoscopy in computed tomography- and positron emission tomography-screened patients with stage I lung cancer. J Thorac Cardiovasc Surg. 2006;131:822–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Herth FJ, Eberhardt R, Vilmann P, Krasnik M, Ernst A. Real-time endobronchial ultrasound guided transbronchial needle aspiration for sampling mediastinal lymph nodes. Thorax. 2006;61:795–8.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Szlubowski A, Kuzdzał J, Kołodziej M, Soja J, Pankowski J, Obrochta A, et al. Endobronchial ultrasound-guided needle aspiration in the non-small cell lung cancer staging. Eur J Cardiothorac Surg. 2009;35:332–5.CrossRefPubMedGoogle Scholar
  25. 25.
    Okada M, Nakayama H, Okumura S, Daisaki H, Adachi S, Yoshimura M, Miyata Y. Multicenter analysis of high-resolution computed tomography and positron emission tomography/computed tomography findings to choose therapeutic strategies for clinical stage IA lung adenocarcinoma. J Thorac Cardiovasc Surg. 2011;141:1384–91.CrossRefPubMedGoogle Scholar

Copyright information

© Springer 2012

Authors and Affiliations

  • Tomoyoshi Takenaka
    • 1
  • Tokujiro Yano
    • 1
  • Yosuke Morodomi
    • 1
  • Kensaku Ito
    • 1
  • Naoko Miura
    • 1
  • Daigo Kawano
    • 1
  • Fumihiro Shoji
    • 1
  • Shingo Baba
    • 2
  • Koichiro Abe
    • 2
  • Hiroshi Honda
    • 2
  • Yoshihiko Maehara
    • 1
  1. 1.Department of Surgery and Science, Graduate School of Medical SciencesKyushu UniversityFukuokaJapan
  2. 2.Department of Clinical Radiology, Graduate School of Medical SciencesKyushu UniversityFukuokaJapan

Personalised recommendations